The AI Arms Race Could Send This Obscure Firm Soaring
The AI arms race could be a massive boom to ONE company that's doing something truly unprecedented. Its new device could become the cornerstone of the next wave of the AI revolution... And early investors could make a substantial sum of money as this story hits the mainstream.
Some Social Security Recipients Won't Have To Wait Until 2026 For COLA Hike
Social Security and SSI recipients will receive a 2.8% cost-of-living adjustment in 2026, with SSI beneficiaries seeing the increase a day earlier due to a federal holiday.
Trump may become the face of economic discontent, a year after such worries helped him win big
WASHINGTON (AP) — President got a serious that he’s out of touch with their fears about a deteriorating U.S. economy.
This Makes NVIDIA Nervous - Ad
NVIDIA's AI chips use huge amounts of power. But a new chip could cut energy use by 99% and run 10 million times more efficiently. One U.S. company has cornered this market. They control the first commercial foundry in America. At under $20 a share, it's a ground-floor shot at the next tech giant.
Trump administration moves to loosen restrictions it once supported on a harmful pollutant
WASHINGTON (AP) — Near the end of his first term, President Donald Trump signed into law a bill that and air conditioners. The bipartisan measure brought environmentalists and major business groups into rare alignment on the contentious issue of climate change and won praise across the political spectrum.
Preliminary tests find germ that causes botulism in ByHeart baby formula
Preliminary tests showed that ByHeart baby formula contained the type of bacteria that produces the toxin linked to , California health officials said.
Investing Legend Hints the End May Be Near for These 3 Iconic Stocks - Ad
Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.
Latest opioid settlement plan with OxyContin maker Purdue and Sackler family getting few objections
NEW YORK (AP) — Lawyers representing OxyContin maker Purdue Pharma, branches of the Sackler family that own it, cities, states, counties, Native American tribes, people with addiction and others across the U.S. are expected to deliver a nearly unanimous message for a bankruptcy court judge Friday: Approve a plan to settle thousands of opioid-related lawsuits against the company.
Babies who drank ByHeart formula got sick months before botulism outbreak, parents say
As health officials investigate more than linked to ByHeart baby formula since August, parents who say their children were sickened with the same illness months before the current outbreak are demanding answers, too.
Elon's New Device Could Launch Biggest IPO of the Decade - Ad
Elon Musk's new device is being called a "game-changer"-and even the White House is using this tech. Jeff Brown says it could launch Musk's next trillion-dollar company and make early investors rich. You can claim a stake now for as little as $500.
Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'
Short seller challenges Praxis' Phase 3 ulixacaltamide data, alleging major flaws that could undermine FDA approval and the company's valuation.
UN secretary general urges nations at climate talks to be flexible to get results
BELEM, Brazil (AP) — U.N. Secretary-General António Guterres on Thursday called for countries at climate talks in Brazil to compromise and “show willingness and flexibility to deliver results,” even if they fall short of the strongest measures some nations want.
"Tech Prophet" Who Predicted the iPhone Now Predicts... - Ad
George Gilder - who predicted the iPhone 17 years early and gave Reagan the first microchip - is making his boldest call yet. He says an American nanotech "super-convergence" could mint more millionaires than any event in recent memory. He's found 3 stocks set to benefit the most.
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Be Well: Breaking down fiber, the next food fad
U.S. consumers who have had their fill of finding to everything from cereal to ice cream are about to meet the next big food fad: fiber.
Trump Signs Law to Launch Dollar 2.0 - Ad
Trump just signed law S.1582, unleashing the biggest money shift in 100+ years. For the first time since 1913, private firms - not the Fed - can mint a "Dollar 2.0." Treasury says it could drain $6.6T from banks and pay 10X current savings rates. Early investors in minting firms could see 40X returns by 2032.
MacArthur Foundation awards $100M to outbreak surveillance network, a boost amid global health cuts
NEW YORK (AP) — The MacArthur Foundation is awarding $100 million to a private pandemic prevention network across Africa, offering critical support to infectious disease surveillance at a time when governments are reducing global health spending.
Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology.
The AI Arms Race Could Send This Obscure Firm Soaring - Ad
The AI arms race could be a massive boom to ONE company that's doing something truly unprecedented. Its new device could become the cornerstone of the next wave of the AI revolution... And early investors could make a substantial sum of money as this story hits the mainstream.
Novo chops Wegovy prices, but doctors still see affordability challenges for patients
Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain challenging for patients without insurance.
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
WASHINGTON (AP) — The Food and Drug Administration said Friday it will add a new warning and other limitations to a that's been linked to .
Is This Elon's Worst Nightmare? - Ad
Elon's empire looks doomed - crashing sales, lost tax credits, and media backlash. But behind the scenes, Tesla is about to unleash a breakthrough Forbes calls a "multi-trillion-dollar opportunity." It's not the end - it's the start of a 25,000% AI comeback.
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.
Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain
Applied Therapeutics stock falls after FDA feedback prompts another Type C meeting to discuss the Phase 3 plan for its CMT-SORD drug govorestat.
Jensen Huang's Secret Masterplan Revealed - Ad
NVIDIA's revolutionary new invention just solved the #1 chokepoint that's been strangling big AI companies. And Tech legend Jeff Brown - the Silicon Valley insider who called NVIDIA before it skyrocketed more than 30,000%... says a shocking announcement by NVIDIA CEO Jensen Huang could make a lot of early investors rich.
Federal workers question whether the longest government shutdown was worth their sacrifice
WASHINGTON (AP) — Jessica Sweet spent cutting back. To make ends meet, the Social Security claims specialist drank only one coffee a day, skipped meals, cut down on groceries and deferred paying some household bills. She racked up spending on her credit card buying gas to get to work.
2 new malaria treatments announced as drug resistance grows
NEW YORK (AP) — Researchers on Wednesday reported two promising new approaches to counteract malaria’s growing resistance to medication — one involving a new class of drugs.
Buy This Gold Stock Before the New Year - Ad
America is about to see a massive shift in how regular people buy and store gold. Next year, the world's largest gold buyer is expected to launch a new way for everyday Americans to invest in gold with a simple tap on their phone - and it could go live in 2026. When it does, a tiny gold stock trading around $1.60 could explode.
More than 80 nonprofits receive $250M for global women's health from Melinda French Gates
More than 80 organizations that provide health care for women all over the world received grants Wednesday totaling after a year-long application process.
House returns for vote to end the government shutdown after nearly 2 months away
WASHINGTON (AP) — House lawmakers will make a long-awaited return to the nation's capital on Wednesday after nearly eight weeks away to potentially put an end to the longest in U.S. history.
Better Than Bitcoin? (Top Crypto for Less Than $1) - Ad
Over the past 15 years, Bitcoin has outperformed stocks, bonds, and every other asset you could've bought. 2025 is already shaping up to be another banner year, with Bitcoin recently hitting a new all-time high. But there's a better way to profit from this new crypto rally. Most people don't know about it... and yet it's returned over 1,000% in 4 months. This could be the #1 way to invest in crypto right now.
Analyst Sees Strong Medtronic Momentum Through 2026 With Buy Rating Intact
BofA expects Medtronic to post over 5% second-quarter revenue growth and maintain strong momentum through 2026, driven by robust procedure trends.
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in resistant hypertension patients.
This Makes NVIDIA Nervous - Ad
NVIDIA's AI chips use huge amounts of power. But a new chip could cut energy use by 99% and run 10 million times more efficiently. One U.S. company has cornered this market. They control the first commercial foundry in America. At under $20 a share, it's a ground-floor shot at the next tech giant.
A deal to end the government shutdown is on track but faces hurdles
WASHINGTON (AP) — A legislative package to end appears on track Monday after a handful of Senate Democrats joined with Republicans to break the impasse in what has become of federal , the longest in history.
Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study
Eledon shares drop as tegoprubart misses the main goal in Phase 2 kidney transplant trial, though safety signals and kidney function data remain encouraging.
Investing Legend Hints the End May Be Near for These 3 Iconic Stocks - Ad
Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.
Oscar Health Misses Q3 Revenue, Loss Widens To $129 Million Despite Membership Surge
Oscar Health's Q3 revenue rose to $2.99 billion on higher membership, but losses widened as risk adjustments offset gains.
Trump unveils deal to expand coverage and lower costs on obesity drugs
WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.